The FDA Just Proposed Killing Compounded GLP-1s for Good — Comment Period Closes June 29

On April 30, 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list. If finalized, this would permanently block large-scale compounding of these GLP-1 medications — even if a new shortage is declared in the future.

The public comment period closes June 29, 2026. Here's what men currently taking compounded GLP-1s need to understand.

What's Actually Happening

This is a separate action from the shortage list removals that happened in 2025. Here's how the two regulatory pathways work:

503A compounding pharmacies (state-licensed, patient-specific) can legally compound copies of approved drugs only when those drugs are on the FDA's shortage list. Since semaglutide and tirzepatide were removed from the shortage list in 2025, 503A pharmacies can no longer compound "essentially a copy" of Ozempic or Wegovy.

503B outsourcing facilities (FDA-registered, large batch) can compound from bulk drug substances if the substance is either on the 503B bulks list OR on the shortage list. Neither GLP-1 currently meets either condition, but no formal exclusion has been issued — until now.

The FDA's proposal would make the exclusion permanent and explicit, closing any future regulatory door for 503B GLP-1 compounding.

What This Means for Men Currently on Compounded GLP-1s

Immediate impact: Limited. Most telehealth-prescribed compounded GLP-1s already flow through 503A pharmacies filling patient-specific prescriptions. The 503B proposal specifically targets large-scale outsourcing facilities, not individual pharmacy compounding under 503A.

Longer-term signal: Clear. The FDA's direction is unmistakable — they view compounded GLP-1s as a temporary phenomenon with no regulatory future in large-scale form. The regulatory walls are closing.

503A vs 503B: Where Your Provider Stands

What to Do Right Now

1. Ask your provider: "Does my compounded semaglutide come from a 503A or 503B facility?" If they can't answer clearly, that's a red flag.
2. Have a backup plan: If your supply chain is 503B-dependent, identify alternative providers now — not after a disruption.
3. Consider brand-name options: Medicare's GLP-1 Bridge ($50/mo starting July 1), Foundayo (new oral option), manufacturer savings programs.
4. Submit comments: If compounded GLP-1s have been important to your care, the FDA is accepting comments through June 29 at regulations.gov.

Providers Using 503A Pharmacies (Not Directly Affected)

These providers compound through patient-specific 503A pharmacies with individual prescriptions: